PolyPid PYPD 深 沪
等待开盘 04-02 09:30:00 美东时间
4.39
+0.010
+0.23%
华盛通- 最 高4.47
- 今 开4.40
- 成交量 7.48万股
- 最 低 4.37
- 昨 收 4.38
- 总市值 8377.54万
- 52周最高 5.12
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 2.44
- 委 比 86.45%
- 总股本 1908.32万
- 历史最高 583.50
- 量 比 1.08
- 振 幅 2.28%
- 历史最低 2.30
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Ltd. has initiated the submission of its New Drug Application (NDA) to the FDA for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs) in colorectal surgery patients. The submission, under the FDA’s Fast Track designation, includes the Chemistry, Manufacturing and Controls (CMC) and nonclinical sections, with the clinical section expected in the second quarter of 2026. D-PLEX₁₀₀, which uses PolyPid’s Kynatrix technology, provid...
03-31 12:30
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
PolyPid Ltd. announced that the FDA has granted a $4.3 million small business waiver for its New Drug Application (NDA) for D-PLEX₁₀₀, aimed at preventing surgical site infections in abdominal colorectal surgeries. This waiver supports the company's commercialization efforts and enables it to focus on submitting the first sections of its rolling NDA by the end of this month. D-PLEX₁₀₀ demonstrated a 60% relative risk reduction in infections in th...
03-17 12:30
美股大行评级 | 杜邦、吉利德科学、Cloudflare、Saia获多家大行上调目标价；Datadog、Robinhood、Klaviyo、Lyft等遭多家大行下调目标价
今日重点评级关注：Benchmark：维持Klaviyo"买入"评级，目标价从30美元升至33美元；富国银行：维持Cloudflare"超配"评级，目标价从265美元升至270美元
02-12 14:02
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.
02-12 02:16
PolyPid Q4 EPS $(0.41) Misses $(0.34) Estimate.
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.34) by 21.66 percent. This is a 63.72 percent increase over losses of $(1.13) per share from the
02-11 20:30
Earnings Scheduled For February 11, 2026
Companies Reporting Before The Bell • SiteOne Landscape Supply (NYSE:SITE) is p...
02-11 19:11
Preview: PolyPid's Earnings
PolyPid (NASDAQ:PYPD) is set to give its latest quarterly earnings report on We...
02-11 04:02
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, will announce its Q4 2025 financial results and operational highlights on February 11, 2026, before the U.S. market open. A conference call and webcast to discuss the results will be held at 8:30 AM Eastern Time. Registration is recommended 5 minutes prior to the call. For those not asking questions, listening via webcast is advised. The company's ...
01-28 13:00
PolyPid Appoints Brooke Story As Board Chairman, Effective Dec. 11
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors,
2025-12-16 21:33
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
PolyPid Ltd. announced the appointment of Brooke Story as Chairman of its Board of Directors. With over 25 years of leadership experience in the MedTech industry, Story will enhance the company’s strategic, commercial, and transaction capabilities. Her expertise in surgical solutions and infection prevention will support PolyPid in advancing its lead product, D-PLEX₁₀₀, which is expected to submit its New Drug Application in early 2026. Story’s l...
2025-12-16 13:30
